CA2807944C - Improved hematopoietic stem and progenitor cell therapy - Google Patents

Improved hematopoietic stem and progenitor cell therapy Download PDF

Info

Publication number
CA2807944C
CA2807944C CA2807944A CA2807944A CA2807944C CA 2807944 C CA2807944 C CA 2807944C CA 2807944 A CA2807944 A CA 2807944A CA 2807944 A CA2807944 A CA 2807944A CA 2807944 C CA2807944 C CA 2807944C
Authority
CA
Canada
Prior art keywords
cells
pge2
population
hematopoietic stem
therapeutic composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2807944A
Other languages
English (en)
French (fr)
Other versions
CA2807944A1 (en
Inventor
Daniel Shoemaker
Pratik MULTANI
Caroline Desponts
L. Robbins David
Paul GRAYSON
John Mendlein
Original Assignee
Fate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fate Therapeutics Inc filed Critical Fate Therapeutics Inc
Publication of CA2807944A1 publication Critical patent/CA2807944A1/en
Application granted granted Critical
Publication of CA2807944C publication Critical patent/CA2807944C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)
CA2807944A 2010-08-12 2011-08-12 Improved hematopoietic stem and progenitor cell therapy Active CA2807944C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37321210P 2010-08-12 2010-08-12
US61/373,212 2010-08-12
PCT/US2011/047657 WO2012021845A2 (en) 2010-08-12 2011-08-12 Improved hematopoietic stem and progenitor cell therapy

Publications (2)

Publication Number Publication Date
CA2807944A1 CA2807944A1 (en) 2012-02-16
CA2807944C true CA2807944C (en) 2020-02-18

Family

ID=45568224

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2807944A Active CA2807944C (en) 2010-08-12 2011-08-12 Improved hematopoietic stem and progenitor cell therapy

Country Status (9)

Country Link
US (2) US20140030232A1 (https=)
EP (2) EP2603227B1 (https=)
JP (7) JP6047489B2 (https=)
CN (5) CN103167876B (https=)
AU (1) AU2011289245B2 (https=)
BR (1) BR112013003366A2 (https=)
CA (1) CA2807944C (https=)
ES (1) ES2654994T3 (https=)
WO (1) WO2012021845A2 (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2654994T3 (es) * 2010-08-12 2018-02-15 Fate Therapeutics, Inc. Terapia mejorada con células madre y precursoras hematopoyéticas
EP2785350B1 (en) 2011-12-02 2018-05-02 Fate Therapeutics, Inc. Improved methods of treating ischemia
JP6220791B2 (ja) 2011-12-02 2017-10-25 フェイト セラピューティクス，インコーポレイテッド 増強された幹細胞組成物
US20150329643A1 (en) 2012-11-16 2015-11-19 Albert Einstein College Of Medicine Of Yeshiva University Identification and use of new tumor-promoting gene in hematological malignancies
KR20210018540A (ko) * 2013-02-18 2021-02-17 유니버시티 헬스 네트워크 다능성 줄기세포로부터 간세포 및 담관세포의 생성 방법
JP2016513974A (ja) * 2013-03-14 2016-05-19 チルドレンズ メディカル センター コーポレーション 造血幹細胞系列を初期化するための組成物および方法
WO2014150602A1 (en) * 2013-03-15 2014-09-25 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
US9943545B2 (en) 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
SG11201507515YA (en) 2013-03-15 2015-10-29 Marcus Kare Torleif Larsson Cells, methods and apparatuses for umbilical cord blood collection and isolation of cells
RU2525143C1 (ru) * 2013-03-22 2014-08-10 Федеральное государственное бюджетное учреждение науки Государственный научный центр Российской Федерации-Институт медико-биологических проблем Российской академии наук СПОСОБ ЭКСПАНСИИ МОНОНУКЛЕАРНЫХ КЛЕТОК ПУПОВИННОЙ КРОВИ (пкМНК) ex vivo В ПРИСУТСТВИИ МУЛЬТИПОТЕНТНЫХ СТРОМАЛЬНЫХ МЕЗЕНХИМАЛЬНЫХ КЛЕТОК (ММСК)
WO2015077691A2 (en) * 2013-11-22 2015-05-28 Washington University Biomarkers for multiple myeloma
WO2016011381A1 (en) 2014-07-18 2016-01-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Reducing cxcr4 expression and/or function to enhance engraftment of hematopoietic stem cells
US20180112180A1 (en) * 2015-01-26 2018-04-26 Fate Therapeutics, Inc. Cells with increased immuno-regulatory properties and methods for their use and manufacture
WO2016123100A1 (en) 2015-01-26 2016-08-04 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
HK1256681A1 (zh) * 2015-04-06 2019-10-04 President And Fellows Of Harvard College 用於非清髓性预处理的组合物和方法
JP7089282B2 (ja) * 2015-07-20 2022-06-22 アンジオクライン・バイオサイエンス・インコーポレイテッド 幹細胞移植のための方法および組成物
US20180214487A1 (en) 2015-07-21 2018-08-02 The Children's Medical Center Corporation Pd-l1 expressing hematopoietic stem cells and uses
SG11201803145RA (en) * 2015-11-04 2018-05-30 Fate Therapeutics Inc Methods and compositions for inducing hematopoietic cell differentiation
KR20250141836A (ko) 2015-11-04 2025-09-29 페이트 세러퓨틱스, 인코포레이티드 만능 세포의 유전자 조작
US11752238B2 (en) * 2016-02-06 2023-09-12 President And Fellows Of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
RU2628092C1 (ru) * 2016-02-10 2017-08-14 Федеральное государственное бюджетное учреждение науки Государственный научный центр Российской Федерации - Институт медико-биологических проблем Российской академии наук (ГНЦ РФ - ИМБП РАН) Способ получения МСК-ассоциированных недифференцированных гемопоэтических клеток-предшественников с фенотипов CD34+/CD133+
CN105779386B (zh) * 2016-04-06 2019-09-20 南京大学 一种间充质干细胞在制备治疗m5型白血病药物中的应用
CN105886457A (zh) * 2016-05-16 2016-08-24 中国人民解放军军事医学科学院野战输血研究所 诱导干细胞分化成外胚层祖细胞的方法
WO2018073615A1 (en) * 2016-10-21 2018-04-26 Longboat Explorers Ab Methods and compositions for generating hematopoietic cells
CN106754726A (zh) * 2016-12-28 2017-05-31 溯源生命科技股份有限公司 一种提高人间充质干细胞移植和归巢效率的基因治疗方法
TW201835798A (zh) * 2017-03-14 2018-10-01 美商歐瑞３恩公司 誘導多能幹細胞之以人類白細胞索引之抗原儲存庫及誘導多能幹細胞衍生之幹細胞及相關系統及方法
US11879137B2 (en) 2017-09-22 2024-01-23 The Children's Medical Center Corporation Treatment of type 1 diabetes and autoimmune diseases or disorders
EP3647413A1 (en) * 2018-10-31 2020-05-06 Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas O.A., M.P. (CIEMAT) Improvements for performing and facilitating the recovery after hematopoietic stem cell transplantation
MX2021014039A (es) * 2019-05-17 2022-02-11 Deverra Therapeutics Inc Composiciones y métodos para mejorar resultados de tratamiento para pacientes que tienen neoplasias malignas hematológicas usando un producto de células madre expandidas.
US20220305057A1 (en) * 2019-06-06 2022-09-29 Medeor Therapeutics, Inc. Methods of making cellular products by post- mortem mobilization and harvesting of hematopoietic cells
US12465878B2 (en) 2019-06-20 2025-11-11 Amniotics Ab Apparatus for filtering amniotic fluid
CN110585432B (zh) * 2019-08-27 2021-10-15 中国人民解放军第二军医大学 成纤维细胞生长因子受体1在制备防治肠道病毒71型感染药物中的应用
EP4234019A3 (en) 2019-10-18 2023-09-13 Amniotics AB Processes and apparatuses for obtaining amniotic mesenchymal stem cells from amniotic fluid and cells derived thereof
US20220411755A1 (en) * 2019-11-14 2022-12-29 Amgen Inc. Hematopoietic precursor cell production
CN116507346A (zh) * 2020-09-24 2023-07-28 广州辑因医疗科技有限公司 化合物用于提高人造血干细胞移植效率的用途
WO2022089606A1 (en) * 2020-10-30 2022-05-05 Westlake Therapeutics (Hangzhou) Co. Limited Methods for preparing mature red blood cells in vitro
US12435308B2 (en) 2020-11-06 2025-10-07 Amniotics Ab Immunomodulation by amniotic fluid mesenchymal stem cells
EP4572775A2 (en) * 2022-08-16 2025-06-25 The Regents of University of California Alleviating graft versus host disease using engineered inkt cells
WO2024186146A1 (ko) * 2023-03-07 2024-09-12 인제대학교 산학협력단 조혈 줄기세포 증식 또는 가동화 촉진용 조성물 및 가동화 조혈 줄기세포 수집방법
WO2026079443A1 (ja) * 2024-10-09 2026-04-16 国立大学法人 東京大学 Ｃｘｃｒ４陽性造血幹細胞の誘導または製造方法および前記ｃｘｃｒ４陽性造血幹細胞を含む細胞集団

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5635387A (en) 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
US5460964A (en) 1992-04-03 1995-10-24 Regents Of The University Of Minnesota Method for culturing hematopoietic cells
US5409813A (en) 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
US5677136A (en) 1994-11-14 1997-10-14 Systemix, Inc. Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof
US5709472A (en) * 1995-10-23 1998-01-20 Lifelines Technology, Inc. Time-temperature indicator device and method of manufacture
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
EP0880598A4 (en) 1996-01-23 2005-02-23 Affymetrix Inc RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM
US5945337A (en) 1996-10-18 1999-08-31 Quality Biological, Inc. Method for culturing CD34+ cells in a serum-free medium
DE69829402T2 (de) 1997-10-31 2006-04-13 Affymetrix, Inc. (a Delaware Corp.), Santa Clara Expressionsprofile in adulten und fötalen organen
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
AU2183900A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
HK1048302A1 (zh) 1999-08-13 2003-03-28 大正制药株式会社 前列腺素衍生物
DE60120007T2 (de) 2000-01-31 2006-11-16 Pfizer Products Inc., Groton Verwendung von Aktivatoren des Prostaglandinrezeptores 4 zur Behandlung von akuter oder chronischer Niereninsuffizienz
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
FR2825261B1 (fr) 2001-06-01 2003-09-12 Maco Pharma Sa Ligne de prelevement du sang placentaire comprenant une poche de rincage
EP1499637A1 (en) * 2002-04-26 2005-01-26 Kirin Beer Kabushiki Kaisha Polypeptide having an activity to support proliferation or survival of hematopoietic stem cell or hematopoietic progenitor cell, and dna coding for the same
US6747037B1 (en) 2003-06-06 2004-06-08 Allergan, Inc. Piperidinyl prostaglandin E analogs
US20050176140A1 (en) * 2004-02-10 2005-08-11 Benedict Daniel J. Method and apparatus for cell culture using a two liquid phase bioreactor
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
JP2008518013A (ja) 2004-10-26 2008-05-29 アラーガン、インコーポレイテッド プロスタグランジンｅｐ４アゴニストによる処置方法およびデリバリー方法
DE102005062741A1 (de) 2005-12-22 2007-06-28 Bayer Schering Pharma Ag Fluorene und Carbazole als Liganden des EP2 Rezeptors
RU2425876C2 (ru) * 2006-03-24 2011-08-10 Чилдрен'З Медикал Сентер Корпорейшн Способ модулирования роста гематопоэтических стволовых клеток
CN101517070A (zh) * 2006-05-31 2009-08-26 Styx有限责任公司 选择干细胞的方法及其用途
CN101506353A (zh) * 2006-06-15 2009-08-12 尼奥斯泰姆公司 外周造血干细胞的处理方法
WO2009134532A2 (en) * 2008-03-07 2009-11-05 The Trustees Of Columbia University In The City Of New York Homing in mesenchymal stem cells
CN108379292A (zh) * 2008-11-06 2018-08-10 印第安纳大学研究与技术公司 增强造血干细胞植入过程的材料和方法
RU2497532C2 (ru) * 2008-12-03 2013-11-10 Эморсайт, Инк. Композиции, улучшающие перфузию в области инфаркта и способы восстановления сосудистого повреждения
JP2010193879A (ja) * 2009-01-27 2010-09-09 Jms Co Ltd 臍帯血造血幹細胞の増殖制御方法およびその用途
ES2654994T3 (es) * 2010-08-12 2018-02-15 Fate Therapeutics, Inc. Terapia mejorada con células madre y precursoras hematopoyéticas

Also Published As

Publication number Publication date
JP6346917B2 (ja) 2018-06-20
BR112013003366A2 (pt) 2020-08-04
JP6047489B2 (ja) 2016-12-21
EP2603227A4 (en) 2014-01-15
JP2023109761A (ja) 2023-08-08
EP2603227A2 (en) 2013-06-19
JP2013540105A (ja) 2013-10-31
CN112501118A (zh) 2021-03-16
CN112516167A (zh) 2021-03-19
JP6574279B2 (ja) 2019-09-11
EP2603227B1 (en) 2017-10-04
CN106244547A (zh) 2016-12-21
JP2020029458A (ja) 2020-02-27
AU2011289245A1 (en) 2013-03-21
WO2012021845A2 (en) 2012-02-16
US20140030232A1 (en) 2014-01-30
CA2807944A1 (en) 2012-02-16
CN103167876B (zh) 2016-08-31
CN106244547B (zh) 2021-01-01
CN106214701A (zh) 2016-12-14
JP2018104457A (ja) 2018-07-05
CN106214701B (zh) 2020-09-25
US20200339953A1 (en) 2020-10-29
AU2011289245B2 (en) 2015-01-22
JP2018184448A (ja) 2018-11-22
JP2022009404A (ja) 2022-01-14
WO2012021845A3 (en) 2012-05-31
ES2654994T3 (es) 2018-02-15
EP3278808A1 (en) 2018-02-07
JP2016185976A (ja) 2016-10-27
CN103167876A (zh) 2013-06-19

Similar Documents

Publication Publication Date Title
CA2807944C (en) Improved hematopoietic stem and progenitor cell therapy
US9943545B2 (en) Stem cell culture media and methods of enhancing cell survival
US8383404B2 (en) Hematopoietic stem cell identification and isolation
AU2019200134B2 (en) Improved hematopoietic stem and progenitor cell therapy
EP2694651A1 (en) Methods and compositions for large-scale isolation of very small embryonic-like (vsel) stem cells
Mizokami et al. Preferential expansion of human umbilical cord blood-derived CD34-positive cells on major histocompatibility complex-matched amnion-derived mesenchymal stem cells
HK1186400B (en) Improved hematopoietic stem and progenitor cell therapy
HK1186400A (en) Improved hematopoietic stem and progenitor cell therapy
HK1186387B (en) Improved hematopoietic stem and progenitor cell therapy
HK1186387A (en) Improved hematopoietic stem and progenitor cell therapy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160729

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250214